ALiCE®: THE FIRST SCALABLE EUKARYOTIC PLATFORM FOR CELL-FREE PROTEIN EXPRESSION

At LenioBio, we believe in the power of proteins. It is our purpose to deliver better access to complex proteins.

High yields in protein expression are key for high-throughput approaches with complex proteins and ultimately, translation into products. LenioBio will provide a range of tools to express proteins in any quantity required, including the notoriously difficult ones, based on the ALiCE® platform.

History: A decade of development

As a novel plant-based cell-free system, ALiCE® was developed within the Fraunhofer Institute (Germany) “Cell-free Bioproduction” Lighthouse Project from 2010–2014 and the federally funded R&D project “building blocks for industrial cell” (see publications). The strategic collaboration with Corteva Agriscience™, the Agriculture Division of DowDuPont™, brought ALiCE® the maturity, competences and funds needed to realize its breakthrough performance of 3000 µg per mL.

Since 2016, LenioBio has been optimizing the system for the expression of pharmaceutical proteins, technical enzymes, and other protein classes, and in March 2018, we obtained exclusive licenses from Dow and Fraunhofer to commercialize the technology under the brand name ALiCE®.

ALiCE®: A scalable platform

The key differentiator of ALiCE® compared with other cell-free expression systems is that its intact protein production machinery reflects that of the living cell. It has an active energy regeneration and includes everything necessary for protein folding, disulfide bonding, and glycosylation. Beyond its ease of use and unprecedented yields, ALiCE® also finally enables fully scalable cell-free eukaryotic expression.

The easy processes and scalability of ALiCE® will drastically reduce the development costs of protein-based products. To date, each scaling step requires adapting living cells in new conditions, which affects productivity and possibly even the protein candidates themselves. For example, the optimization of protein expression when scaling up recombinant CHO cells can take more than one year. Scaling up in ALiCE® sidesteps many of the complexities of cell-based systems and allows for much faster process development.

LenioBio will be realizing the potential of ALiCE® by merging the superior productivity, the unique ease of use (“just add the DNA”), the capability of expressing complex proteins, humanized glycosylation and its  cost-effective structure into one platform.

ALiCE®: Publications by peers

Scientific reports where ALiCE® (>3 mg/mL) is applied will be published soon.

The Fraunhofer Institute IME have been working on the precursor of ALiCE® (up to 0.4 mg/mL) for an extended period and the experiences of our peers can be found in the following publications:

Buntru et al. Tobacco BY-2 cell-free lysate: an alternative and highly-productive plant-based in vitro translation system. BMC Biotechnology 2014;14:37. https://doi.org/10.1186/1472-6750-14-37

Buntru et al. A versatile coupled cell-free transcription–translation system based on tobacco BY-2 cell lysates. Biotechnology and Bioengineering 2015;112(5):867–878.

Havenith et al. Combination of two epitope identification techniques enables the rational design of soy allergen Gly m 4 mutants. Biotechnology Journal 2017;12:1600441. https://doi.org/10.1002/biot.201600441

Huck et al. Combined 15N-labeling and TandemMOAC quantifies phosphorylation of MAP kinase substrates downstream of MKK7 in Arabidopsis. Frontiers in Plant Science 2017;8:2050. https://doi.org/10.3389/fpls.2017.02050

Ready to try ALiCE® for yourself?
Order now or contact an expert with your questions.